Precigen (PGEN) Competitors

$4.42 -0.18 (-3.91%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$4.39 -0.03 (-0.68%)

As of 05/15/2026 07:23 PM Eastern

PGEN vs. COGT, CNTA, IMVT, SRRK, and GRFS

Should you buy Precigen stock or one of its competitors? MarketBeat compares Precigen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precigen include Cogent Biosciences (COGT), Centessa Pharmaceuticals (CNTA), Immunovant (IMVT), Scholar Rock (SRRK), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Precigen compare to Cogent Biosciences?

Precigen (NASDAQ:PGEN) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

33.5% of Precigen shares are held by institutional investors. 47.1% of Precigen shares are held by insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Precigen had 22 more articles in the media than Cogent Biosciences. MarketBeat recorded 25 mentions for Precigen and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.29 beat Precigen's score of 0.33 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen presently has a consensus target price of $11.00, indicating a potential upside of 148.87%. Cogent Biosciences has a consensus target price of $43.73, indicating a potential upside of 33.80%. Given Precigen's higher probable upside, equities research analysts plainly believe Precigen is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cogent Biosciences has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Cogent Biosciences	N/A	-104.27%	-54.64%

Precigen has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	162.79	-$250.64M	-$1.18	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Precigen has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Summary

Precigen beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

How does Precigen compare to Centessa Pharmaceuticals?

Precigen (NASDAQ:PGEN) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Precigen has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

In the previous week, Precigen had 20 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 25 mentions for Precigen and 5 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.41 beat Precigen's score of 0.33 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Centessa Pharmaceuticals has higher revenue and earnings than Precigen. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	162.79	-$250.64M	-$1.18	N/A
Centessa Pharmaceuticals	$15M	393.87	-$197.53M	-$1.79	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Precigen currently has a consensus target price of $11.00, indicating a potential upside of 148.87%. Centessa Pharmaceuticals has a consensus target price of $40.70, indicating a potential upside of 2.80%. Given Precigen's stronger consensus rating and higher probable upside, research analysts clearly believe Precigen is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

33.5% of Precigen shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 47.1% of Precigen shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Precigen and Centessa Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Precigen compare to Immunovant?

Precigen (NASDAQ:PGEN) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Precigen has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

In the previous week, Precigen had 21 more articles in the media than Immunovant. MarketBeat recorded 25 mentions for Precigen and 4 mentions for Immunovant. Immunovant's average media sentiment score of 0.89 beat Precigen's score of 0.33 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	162.79	-$250.64M	-$1.18	N/A
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A

Immunovant has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Immunovant	N/A	-63.17%	-58.01%

Precigen currently has a consensus target price of $11.00, indicating a potential upside of 148.87%. Immunovant has a consensus target price of $32.44, indicating a potential upside of 18.02%. Given Precigen's higher probable upside, research analysts clearly believe Precigen is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

33.5% of Precigen shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 47.1% of Precigen shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Precigen beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Precigen compare to Scholar Rock?

Precigen (NASDAQ:PGEN) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Precigen had 6 more articles in the media than Scholar Rock. MarketBeat recorded 25 mentions for Precigen and 19 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.78 beat Precigen's score of 0.33 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Scholar Rock	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Scholar Rock	N/A	-163.52%	-96.67%

Precigen currently has a consensus target price of $11.00, indicating a potential upside of 148.87%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 13.48%. Given Precigen's higher possible upside, equities research analysts plainly believe Precigen is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17

33.5% of Precigen shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 47.1% of Precigen shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Precigen has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	162.79	-$250.64M	-$1.18	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Precigen has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Summary

Precigen beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

How does Precigen compare to Grifols?

Precigen (NASDAQ:PGEN) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Precigen had 22 more articles in the media than Grifols. MarketBeat recorded 25 mentions for Precigen and 3 mentions for Grifols. Grifols' average media sentiment score of 0.96 beat Precigen's score of 0.33 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Grifols	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Grifols has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

33.5% of Precigen shares are held by institutional investors. 47.1% of Precigen shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Precigen currently has a consensus target price of $11.00, indicating a potential upside of 148.87%. Grifols has a consensus target price of $10.00, indicating a potential upside of 30.55%. Given Precigen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Precigen is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Grifols has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	162.79	-$250.64M	-$1.18	N/A
Grifols	$7.44B	0.70	$454.82M	$0.19	40.32

Grifols has a net margin of 5.54% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Grifols	5.54%	6.21%	2.39%

Summary

Precigen beats Grifols on 10 of the 16 factors compared between the two stocks.

Get Precigen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGEN vs. The Competition

Export

Metric	Precigen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.58B	$3.31B	$6.38B	$12.30B
Dividend Yield	N/A	2.35%	2.81%	5.27%
P/E Ratio	-3.75	18.50	20.66	25.27
Price / Sales	162.79	284.70	551.98	75.61
Price / Cash	N/A	121.77	42.43	54.86
Price / Book	73.67	6.63	9.87	6.90
Net Income	-$250.64M	$24.40M	$3.57B	$334.66M
7 Day Performance	4.99%	4.14%	0.23%	0.12%
1 Month Performance	11.06%	-4.80%	-2.54%	-0.18%
1 Year Performance	204.83%	62.87%	33.54%	30.62%

Precigen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGEN Precigen	3.6371 of 5 stars	$4.42 -3.9%	$11.00 +148.9%	+204.8%	$1.58B	$9.68M	N/A	190	Trending News Earnings Report Analyst Forecast Analyst Revision
COGT Cogent Biosciences	3.1773 of 5 stars	$34.10 -1.8%	$43.73 +28.2%	+569.7%	$5.94B	N/A	N/A	80	Positive News
CNTA Centessa Pharmaceuticals	2.0854 of 5 stars	$39.59 flat	$40.70 +2.8%	+216.5%	$5.91B	N/A	N/A	200
IMVT Immunovant	2.2715 of 5 stars	$29.06 +0.4%	$32.44 +11.6%	+90.1%	$5.89B	N/A	N/A	120
SRRK Scholar Rock	2.4261 of 5 stars	$48.35 -0.1%	$56.00 +15.8%	+61.5%	$5.80B	N/A	N/A	140	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGEN) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precigen (PGEN) Competitors

PGEN vs. COGT, CNTA, IMVT, SRRK, and GRFS

How does Precigen compare to Cogent Biosciences?

Summary

How does Precigen compare to Centessa Pharmaceuticals?

Summary

How does Precigen compare to Immunovant?

Summary

How does Precigen compare to Scholar Rock?

Summary

How does Precigen compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precigen (PGEN) Competitors

PGEN vs. COGT, CNTA, IMVT, SRRK, and GRFS

How does Precigen compare to Cogent Biosciences?

Do insiders & institutionals believe in PGEN or COGT?

Does the media favor PGEN or COGT?

Do analysts recommend PGEN or COGT?

Is PGEN or COGT more profitable?

Which has preferable valuation and earnings, PGEN or COGT?

Which has more volatility and risk, PGEN or COGT?

Summary

How does Precigen compare to Centessa Pharmaceuticals?

Which has more volatility & risk, PGEN or CNTA?

Does the media prefer PGEN or CNTA?

Which has preferable earnings & valuation, PGEN or CNTA?

Is PGEN or CNTA more profitable?

Do analysts rate PGEN or CNTA?

Do institutionals and insiders have more ownership in PGEN or CNTA?

Summary

How does Precigen compare to Immunovant?

Which has more volatility & risk, PGEN or IMVT?

Does the media prefer PGEN or IMVT?

Which has preferable earnings & valuation, PGEN or IMVT?

Is PGEN or IMVT more profitable?

Do analysts rate PGEN or IMVT?

Do institutionals and insiders have more ownership in PGEN or IMVT?

Summary

How does Precigen compare to Scholar Rock?

Does the media prefer PGEN or SRRK?

Is PGEN or SRRK more profitable?

Do analysts recommend PGEN or SRRK?

Do institutionals and insiders believe in PGEN or SRRK?

Which has preferable valuation & earnings, PGEN or SRRK?

Which has more risk & volatility, PGEN or SRRK?

Summary

How does Precigen compare to Grifols?

Does the media prefer PGEN or GRFS?

Which has more risk & volatility, PGEN or GRFS?

Do institutionals and insiders believe in PGEN or GRFS?

Do analysts recommend PGEN or GRFS?

Which has preferable valuation & earnings, PGEN or GRFS?

Is PGEN or GRFS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools